Summit Therapeutics Inc.
SMMT
Peringkat dalam Saham
#1720
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$15.34
Kapitalisasi Pasar
$12.24B
Perubahan (1 hari)
-3.10%
Perubahan (1 tahun)
-19.94%
Negara
US
Perdagangan Summit Therapeutics Inc. (SMMT)
Kategori
Healthcare
Riwayat harga saham Summit Therapeutics Inc. (SMMT)
Harga penutupan tertinggi: $16.33 pada 2026-10-01
Harga penutupan terendah: $11.32 pada 2015-03-01
Harga penutupan terendah: $11.32 pada 2015-03-01
Riwayat harga saham Summit Therapeutics Inc. dari 2015 hingga 2026
Performa harga saham tahunan
| Tahun | Performa |
|---|---|
| 2026 (TTM) | -6.38% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Harga saham perusahaan atau pesaing serupa
| Perusahaan | Harga saham | Perubahan 1th% | Negara |
|---|---|---|---|
| $535.81 | 25.65% |
US
|
|
| $188.41 | 601.69% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $890.95 | 9.43% |
NL
|
